Ann: Positive PDCO opinion and A$20m Placement, page-69

RC,

The market is a forward looking instrument.

The market will value the unique opportunity here...way ahead of revenue!

ATL1102 will be a First in Class + Best in Class drug...protected by ODD for 7 - 10 years.

We are talking $4B per year market just for non-ambulant boys (EU/US).

Say they attain only 50% of the market - that is still $2B per year revenue.

Currently we are sitting at sub $150m market cap.

So...soon we start the value accretion in line with FA progress.

The only way is up...baby...for you and me!
.